The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors
Authors:
- Vanessa AlmendroVAVanessa Almendro
- Andriy MarusykAMAndriy Marusyk
- Michail ShipitsinMSMichail Shipitsin
- Janina SchemmeJSJanina Schemme
- Sarah R. WalkerSWSarah R. Walker
- Noga Bloushtain-QimronNBNoga Bloushtain-Qimron
- Jessica J. KimJKJessica J. Kim
- Sibgat A. ChoudhurySCSibgat A. Choudhury
- Reo MaruyamaRMReo Maruyama
- Zhenhua WuZWZhenhua Wu
- Mithat GönenMGMithat Gönen
Top Cited Papers
Open Access
- 1 July 2011
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 121 (7) , 2723-2735
Abstract
Intratumor heterogeneity is a major clinical problem because tumor cell subtypes display variable sensitivity to therapeutics and may play different roles in progression. We previously characterized 2 cell populations in human breast tumors with distinct properties: CD44+CD24– cells that have stem cell-like characteristics, and CD44–CD24+ cells that resemble more differentiated breast cancer cells. Here we identified 15 genes required for cell growth or proliferation in CD44+CD24– human breast cancer cells in a large-scale loss-of-function screen and found that inhibition of several of these (IL6, PTGIS, HAS1, CXCL3, and PFKFB3) reduced Stat3 activation. We found that the IL-6/JAK2/Stat3 pathway was preferentially active in CD44+CD24– breast cancer cells compared with other tumor cell types, and inhibition of JAK2 decreased their number and blocked growth of xenografts. Our results highlight the differences between distinct breast cancer cell types and identify targets such as JAK2 and Stat3 that may lead to more specific and effective breast cancer therapies.Keywords
This publication has 64 references indexed in Scilit:
- IKK/NF‐κB and STAT3 pathways: central signalling hubs in inflammation‐mediated tumour promotion and metastasisEMBO Reports, 2009
- An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell TransformationCell, 2009
- Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating featuresProceedings of the National Academy of Sciences, 2009
- The Increasing Complexity of the Cancer Stem Cell ParadigmScience, 2009
- STAT3 as a Central Regulator of Tumor MetastasesCurrent Molecular Medicine, 2009
- CXCR2 antagonists for the treatment of pulmonary diseasePharmacology & Therapeutics, 2009
- Purification and Characterization of Recombinant Human Prostacyclin SynthaseThe Journal of Biochemistry, 2004
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Autocrine-mediated Activation of STAT3 Correlates with Cell Proliferation in Breast Carcinoma LinesJournal of Biological Chemistry, 2002